$238 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 36 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 70.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AADI BIOSCIENCES INC | $36,935,000 | -17.8% | 1,529,402 | 0.0% | 15.52% | -2.0% | ||
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $25,295,000 | +916.7% | 535,000 | +608.6% | 10.63% | +1110.9% |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $22,886,000 | -28.8% | 11,736,283 | +0.1% | 9.62% | -15.2% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC | $13,141,000 | -27.9% | 340,098 | +0.8% | 5.52% | -14.1% |
| GHRS | Buy | GH RESEARCH PLCordinary shares | $9,790,000 | +12.9% | 419,632 | +6.7% | 4.12% | +34.4% |
| RLMD | New | RELMADA THERAPEUTICS INC | $9,102,000 | – | 404,000 | +100.0% | 3.83% | – |
| BLSA | BCLS ACQUISITION CORP- CL A | $8,263,000 | -1.6% | 843,122 | 0.0% | 3.47% | +17.2% | |
| ISEE | Sell | IVERIC BIO INC | $7,858,000 | -57.4% | 470,000 | -58.6% | 3.30% | -49.2% |
| MRUS | Buy | MERUS BV | $7,489,000 | +179.0% | 235,500 | +93.0% | 3.15% | +232.4% |
| New | PYXIS ONCOLOGY INC SERIES B | $7,435,000 | – | 677,753 | +100.0% | 3.12% | – | |
| XENE | Sell | XENON PHARMACEUTICALS INC | $7,029,000 | +10.2% | 225,000 | -46.1% | 2.96% | +31.3% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS INC | $6,995,000 | -7.8% | 105,500 | -13.2% | 2.94% | +9.9% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $6,287,000 | +181.4% | 318,000 | +134.2% | 2.64% | +235.4% |
| JYAC | JIYA ACQUISITION CORP -CL A | $5,496,000 | +0.2% | 562,500 | 0.0% | 2.31% | +19.4% | |
| New | AVADEL PHARMACEUTICALS PLCsponsored adr | $4,686,000 | – | 580,000 | +100.0% | 1.97% | – | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $4,512,000 | +14.5% | 206,126 | 0.0% | 1.90% | +36.5% | |
| CYT | CYTEIR THERAPEUTICS INC | $4,457,000 | -35.2% | 391,974 | 0.0% | 1.87% | -22.8% | |
| BLU | Sell | BELLUS HEALTH INC | $4,226,000 | -65.7% | 525,000 | -73.8% | 1.78% | -59.2% |
| KURA | KURA ONCOLOGY INC. COMMON STOCK | $4,086,000 | -25.3% | 291,884 | 0.0% | 1.72% | -11.0% | |
| SEEL | Sell | SEELOS THERAPEUTICS INC | $4,075,000 | -40.9% | 2,500,000 | -12.6% | 1.71% | -29.6% |
| ATHA | Buy | ATHIRA PHARMA INC | $4,040,000 | +44.9% | 310,030 | +4.3% | 1.70% | +72.6% |
| HSAQ | HEALTH SCIENCES ACQUISITIONS | $3,956,000 | +1.9% | 392,500 | 0.0% | 1.66% | +21.4% | |
| VSTM | Sell | VERASTEM INC | $3,823,000 | -38.5% | 1,865,000 | -7.6% | 1.61% | -26.8% |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $3,538,000 | -61.1% | 200,000 | -38.0% | 1.49% | -53.7% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $3,436,000 | -62.8% | 179,995 | -51.9% | 1.44% | -55.7% |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $3,186,000 | – | 230,000 | +100.0% | 1.34% | – |
| EYPT | Sell | EYEPOINT PHARMACEUTICALS INC | $2,975,000 | -22.8% | 243,072 | -34.3% | 1.25% | -8.1% |
| MRTX | New | MIRATI THERAPEUTICS | $2,934,000 | – | 20,000 | +100.0% | 1.23% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $2,000,000 | – | 500,000 | +100.0% | 0.84% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $1,489,000 | – | 68,500 | +100.0% | 0.63% | – |
| ACRS | Sell | ACLARIS THERAPEU | $1,425,000 | -43.8% | 98,000 | -30.4% | 0.60% | -33.0% |
| GOSS | Sell | GOSSAMER BIO INC | $1,355,000 | -49.9% | 119,843 | -44.3% | 0.57% | -40.3% |
| MTEM | New | MOLECULAR TEMPLATES INC | $1,264,000 | – | 322,500 | +100.0% | 0.53% | – |
| GRTX | New | GALERA THERAPEUTICS INC | $1,205,000 | – | 262,500 | +100.0% | 0.51% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $1,065,000 | – | 127,500 | +100.0% | 0.45% | – |
| NUVB | New | Nuvation Warrants*w exp 07/07/202 | $172,000 | – | 90,832 | +100.0% | 0.07% | – |
| NUVBWS | Exit | NUVATION BIO INC*w exp 07/07/202 | $0 | – | -90,832 | -100.0% | -0.08% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -2,315 | -100.0% | -0.17% | – |
| UTHR | Exit | UNITED THERAPEUTICS DEL | $0 | – | -3,000 | -100.0% | -0.20% | – |
| ELAN | Exit | ELANCO ANIMAL HEALTH | $0 | – | -29,000 | -100.0% | -0.33% | – |
| CCCC | Exit | C4 THERAPEUTICS STK | $0 | – | -21,000 | -100.0% | -0.33% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -301,904 | -100.0% | -0.39% | – |
| CMRX | Exit | CHIMERIX | $0 | – | -210,000 | -100.0% | -0.46% | – |
| Exit | ASTRIA THERAPEUTICS | $0 | – | -156,927 | -100.0% | -0.49% | – | |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -60,000 | -100.0% | -0.52% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -365,000 | -100.0% | -0.53% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLC SPONSORED ADSsponsored ads | $0 | – | -38,184 | -100.0% | -0.56% | – |
| ALT | Exit | ALTIMMUNE | $0 | – | -150,000 | -100.0% | -0.60% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -17,500 | -100.0% | -0.62% | – |
| ALLK | Exit | ALLAKOS | $0 | – | -17,500 | -100.0% | -0.65% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCcall | $0 | – | -250,000 | -100.0% | -0.86% | – |
| RAIN | Exit | RAIN THERAPEUTICS INC | $0 | – | -182,500 | -100.0% | -0.96% | – |
| CABA | Exit | CABALETTA BIO | $0 | – | -302,926 | -100.0% | -1.30% | – |
| KRYS | Exit | KRYSTAL BIOTECH | $0 | – | -72,551 | -100.0% | -1.34% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS | $0 | – | -150,500 | -100.0% | -1.46% | – |
| VINC | Exit | VINCERX PHARMA INC | $0 | – | -260,000 | -100.0% | -1.48% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -1,024,668 | -100.0% | -1.50% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -1,316,268 | -100.0% | -2.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.